hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirotiká na systémové použitie - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastické činidlá - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
vedida 200 mg prášok na infúzny roztok
medochemie ltd., cyprus - vorikonazol - 26 - antimycotica (lokÁlne a celkovÉ)
voriconazole hameln 200 mg prášok na infúzny roztok
hameln pharma gmbh, nemecko - vorikonazol - 26 - antimycotica (lokÁlne a celkovÉ)
voriconazole agmed 200 mg
agmed s.r.o., Česká republika - vorikonazol - 26 - antimycotica (lokÁlne a celkovÉ)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukémia, lymfocytárna, chronická, b-bunka - antineoplastické činidlá - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.